GlassScriptPhysician profile
Alyssa A Shaw
NPI 1689636011
$4,535.77
in general payments reported to CMS, 2019-2025
38 companies · $1,234 in 2025
The $1,234 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $343 · 2021: $139 · 2022: $67.26 · 2023: $1,268 · 2024: $510 · 2025: $1,234.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,544 · Travel and Lodging: $446 · Education: $23.04.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,543.61 |
| Travel and Lodging | $446.46 |
| Education | $23.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,078.82 | 2024-2025 | Watchman, Watchman Access System, Watchman Flx |
| Pfizer INC. | $358.06 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $318.92 | 2019-2024 | Xarelto, Spravato |
| Abbvie INC. | $238.34 | 2019-2024 | Synthroid, Linzess, Viberzi |
| Glaxosmithkline, LLC. | $209.20 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Amarin Pharma, INC. | $209.19 | 2019-2021 | |
| Amgen INC. | $184.60 | 2019-2024 | Otezla, Repatha, Prolia |
| Novo Nordisk INC | $175.98 | 2019-2024 | Ozempic, Tresiba, Rybelsus |
| Allergan, INC. | $165.22 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $149.27 | 2019-2024 | Breztri, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.78 | 2019-2023 | Jardiance |
| Phathom Pharmaceuticals, INC. | $125.00 | 2025 | Voquezna |
| Lilly USA, LLC | $121.55 | 2019-2024 | Mounjaro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $105.28 | 2019-2023 | Trulance, Xifaxan |
| Abbott Laboratories | $104.58 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Shaw listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.